Publikationen in Zusammenarbeit mit Forschern von University Hospital Aachen (6)

2022

  1. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

    Leukemia, Vol. 36, Núm. 7, pp. 1825-1833

  2. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option

    Blood Reviews, Vol. 56

  3. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis

    International Journal of Hematology, Vol. 115, Núm. 6, pp. 838-851

2020

  1. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

    Leukemia, Vol. 34, Núm. 8, pp. 2125-2137

2019

  1. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

    Journal of Cancer Research and Clinical Oncology, Vol. 145, Núm. 6, pp. 1589-1599

2018

  1. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial

    Journal of Clinical Oncology, Vol. 36, Núm. 3, pp. 231-237